Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Wedbush digital media analyst to hold an analyst/industry conference call » 15:36
08/07/20
08/07
15:36
08/07/20
15:36
ATVI

Activision Blizzard

$82.24 /

-4.68 (-5.38%)

, EA

Electronic Arts

$143.35 /

-3.57 (-2.43%)

, GME

GameStop

$4.14 /

-0.29 (-6.55%)

, NTDOY

Nintendo

$0.00 /

+ (+0.00%)

, TTWO

Take-Two

$173.82 /

-3.66 (-2.06%)

, UBSFY

Ubisoft

$0.00 /

+ (+0.00%)

Digital Media Analyst…

Digital Media Analyst Pachter provides a recap of video game sales on an Analyst/Industry conference call to be held on August 14 at 10:30 am.

ShowHide Related Items >><<
UBSFY Ubisoft
$0.00 /

+ (+0.00%)

TTWO Take-Two
$173.82 /

-3.66 (-2.06%)

NTDOY Nintendo
$0.00 /

+ (+0.00%)

GME GameStop
$4.14 /

-0.29 (-6.55%)

EA Electronic Arts
$143.35 /

-3.57 (-2.43%)

ATVI Activision Blizzard
$82.24 /

-4.68 (-5.38%)

ATVI Activision Blizzard
$82.24 /

-4.68 (-5.38%)

08/05/20 Barclays
Activision Blizzard price target raised to $98 from $90 at Barclays
08/05/20 Morgan Stanley
Activision Blizzard price target raised to $100 from $88 at Morgan Stanley
08/05/20 UBS
Activision Blizzard price target raised to $106 from $84 at UBS
08/05/20 Oppenheimer
Activision Blizzard price target raised to $95 from $75 at Oppenheimer
EA Electronic Arts
$143.35 /

-3.57 (-2.43%)

07/31/20
Fly Intel: Top five analyst upgrades
07/31/20 JPMorgan
Electronic Arts price target raised to $150 from $127 at JPMorgan
07/31/20 MKM Partners
Electronic Arts price target raised to $160 from $144 at MKM Partners
07/31/20 KeyBanc
Electronic Arts upgraded to Overweight from Sector Weight at KeyBanc
GME GameStop
$4.14 /

-0.29 (-6.55%)

06/11/20 Ascendiant
GameStop price target raised to $4 from $3 at Ascendiant
06/10/20 Baird
GameStop significant challenges remain ahead, says Baird
04/21/20 Baird
GameStop FY20 EPS target cut at Baird
03/27/20 Baird
GameStop trneds to remain weak despite recent increase, says Baird
NTDOY Nintendo
$0.00 /

+ (+0.00%)

07/29/20 Goldman Sachs
Nintendo resumed with a Buy at Goldman Sachs
07/16/20 Citi
Nintendo price target raised to 59,000 yen from 47,000 yen at Citi
06/24/20
Fly Intel: Top five analyst downgrades
06/24/20 Wedbush
Nintendo downgraded to Neutral at Wedbush as catalysts may prove 'elusive'
TTWO Take-Two
$173.82 /

-3.66 (-2.06%)

08/04/20
Fly Intel: Top five analyst downgrades
08/04/20 MKM Partners
Take-Two price target raised to $190 from $165 at MKM Partners
08/04/20 Wedbush
Take-Two price target raised to $210 from $170 at Wedbush
08/04/20 Oppenheimer
Take-Two price target raised to $190 from $155 at Oppenheimer
UBSFY Ubisoft
$0.00 /

+ (+0.00%)

07/23/20 JPMorgan
Ubisoft price target raised to EUR 82 from EUR 79 at JPMorgan
07/17/20 Oddo BHF
Ubisoft downgraded to Neutral from Buy at Oddo BHF
07/13/20 Jefferies
Ubisoft downgraded to Hold from Buy at Jefferies
07/13/20 Societe Generale
Ubisoft downgraded to Hold from Buy at Societe Generale
UBSFY Ubisoft
$0.00 /

+ (+0.00%)

TTWO Take-Two
$173.82 /

-3.66 (-2.06%)

NTDOY Nintendo
$0.00 /

+ (+0.00%)

GME GameStop
$4.14 /

-0.29 (-6.55%)

EA Electronic Arts
$143.35 /

-3.57 (-2.43%)

ATVI Activision Blizzard
$82.24 /

-4.68 (-5.38%)

UBSFY Ubisoft
$0.00 /

+ (+0.00%)

TTWO Take-Two
$173.82 /

-3.66 (-2.06%)

NTDOY Nintendo
$0.00 /

+ (+0.00%)

GME GameStop
$4.14 /

-0.29 (-6.55%)

EA Electronic Arts
$143.35 /

-3.57 (-2.43%)

ATVI Activision Blizzard
$82.24 /

-4.68 (-5.38%)

TTWO Take-Two
$173.82 /

-3.66 (-2.06%)

NTDOY Nintendo
$0.00 /

+ (+0.00%)

GME GameStop
$4.14 /

-0.29 (-6.55%)

EA Electronic Arts
$143.35 /

-3.57 (-2.43%)

ATVI Activision Blizzard
$82.24 /

-4.68 (-5.38%)

TTWO Take-Two
$173.82 /

-3.66 (-2.06%)

GME GameStop
$4.14 /

-0.29 (-6.55%)

EA Electronic Arts
$143.35 /

-3.57 (-2.43%)

ATVI Activision Blizzard
$82.24 /

-4.68 (-5.38%)

Thursday
Options
Dave & Buster's call volume above normal and directionally bullish » 12:25
08/06/20
08/06
12:25
08/06/20
12:25
PLAY

Dave & Buster's

$13.18 /

+0.215 (+1.66%)

Bullish option flow…

Bullish option flow detected in Dave & Buster's with 7,685 calls trading, 1.4x expected, and implied vol increasing almost 3 points to 105.72%. 8/7 weekly 13.5 calls and 8/14 weekly 14.5 calls are the most active options, with total volume in those strikes near 3,500 contracts. The Put/Call Ratio is 0.30. Earnings are expected on September 8th.

ShowHide Related Items >><<
PLAY Dave & Buster's
$13.18 /

+0.215 (+1.66%)

PLAY Dave & Buster's
$13.18 /

+0.215 (+1.66%)

06/12/20
Fly Intel: Top five analyst upgrades
06/12/20 BMO Capital
Dave & Buster's price target raised to $15 from $13 at BMO Capital
06/12/20
Dave & Buster's upgraded to Buy at SunTrust on growing sales at reopened stores
06/12/20 Truist
Dave & Buster's upgraded to Buy from Hold at SunTrust
PLAY Dave & Buster's
$13.18 /

+0.215 (+1.66%)

  • 04
    May
PLAY Dave & Buster's
$13.18 /

+0.215 (+1.66%)

PLAY Dave & Buster's
$13.18 /

+0.215 (+1.66%)

Earnings
Lantronix sees Q4 revenue $17.1M-$17.6M, consensus $17.07M » 07:37
08/06/20
08/06
07:37
08/06/20
07:37
LTRX

Lantronix

$4.35 /

-0.055 (-1.25%)

For the fourth quarter of…

For the fourth quarter of fiscal 2020, Lantronix expects to report net revenues of $17.1 to $17.6 million, up 4% to 7% sequentially, and up 68% to 73% year over year. The company further expects that GAAP and non-GAAP earnings will grow sequentially from the third quarter of fiscal 2020 and reports that cash grew sequentially to $7.7 million. Due to difficulties in forecasting as a result of supply chain disruptions related to the COVID-19 pandemic, management had previously guided for sequential revenue and earnings growth for the fourth quarter of fiscal 2020, with no further specificity. "We continue to work through supply chain disruptions and expect to deliver strong sequential and year over year revenue growth in our fourth fiscal quarter results," stated Paul Pickle, president and CEO of Lantronix. "While COVID-19-related supply chain disruptions create some challenges in our ability to forecast in the near term, the surge in remote management demand and expanding engagements in work-from-home initiatives with multiple manufacturers leave us with an improving outlook for fiscal 2021."

ShowHide Related Items >><<
LTRX Lantronix
$4.35 /

-0.055 (-1.25%)

LTRX Lantronix
$4.35 /

-0.055 (-1.25%)

05/15/20 Lake Street
Lantronix 'relatively upbeat tone' encouraging, says Lake Street
03/12/20 Lake Street
Lantronix price target lowered to $5 from $6 at Lake Street
02/18/20 Roth Capital
Lantronix initiated with a Buy at Roth Capital
LTRX Lantronix
$4.35 /

-0.055 (-1.25%)

Wednesday
Hot Stocks
Sony says State of Play returns this Thursday, August 6 » 15:05
08/05/20
08/05
15:05
08/05/20
15:05
ATVI

Activision Blizzard

$84.15 /

-2.19 (-2.54%)

, TTWO

Take-Two

$176.18 /

-1.07 (-0.60%)

, GME

GameStop

$4.59 /

+0.16 (+3.61%)

, NTDOY

Nintendo

$0.00 /

+ (+0.00%)

, EA

Electronic Arts

$145.54 /

-0.77 (-0.53%)

, UBSFY

Ubisoft

$0.00 /

+ (+0.00%)

, MSFT

Microsoft

$212.86 /

-0.46 (-0.22%)

, FB

Facebook

$250.14 /

+0.7 (+0.28%)

, AMZN

Amazon.com

$3,202.57 /

+66.59 (+2.12%)

Sid Shuman Senior…

Sid Shuman Senior Director, SIE (SNE) Content Communication said in a blog post: "It's been a while... but State of Play returns this Thursday with a focus on third-party-published games coming to PS4 and PS VR. We'll have a few PS5 game updates on third-party and indie titles you last saw in June's PS5 showcase. The episode is weighing in at 40+ minutes(!). We've got a great lineup in store featuring plenty of new gameplay footage and other game updates. Can't wait to hear what you think! And just to be super clear - there will be no PlayStation Studios updates in Thursday's episode. There won't be any updates around hardware, business, preorders, or dates either. On Thursday, our focus is squarely on showcasing some cool upcoming games coming to the broader PlayStation ecosystem. Should be fun! The new State of Play episode airs Thursday, August 6 at 1:00pm Pacific Time / 4:00pm Eastern Time / 9:00pm BST, and you can watch it live on Twitch and YouTube. See you Thursday!" Other publicly traded companies that may be impacted by this event include: Activision Blizzard (ATVI), Electronic Arts (EA), GameStop (GME), Nintendo (NTDOY), Take-Two (TTWO) and Ubisoft (UBSFY), Microsoft (MSFT), Facebook (FB) and Amazon (AMZN). Reference Link

ShowHide Related Items >><<
UBSFY Ubisoft
$0.00 /

+ (+0.00%)

TTWO Take-Two
$176.18 /

-1.07 (-0.60%)

NTDOY Nintendo
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.86 /

-0.46 (-0.22%)

GME GameStop
$4.59 /

+0.16 (+3.61%)

FB Facebook
$250.14 /

+0.7 (+0.28%)

EA Electronic Arts
$145.54 /

-0.77 (-0.53%)

ATVI Activision Blizzard
$84.15 /

-2.19 (-2.54%)

AMZN Amazon.com
$3,202.57 /

+66.59 (+2.12%)

ATVI Activision Blizzard
$84.15 /

-2.19 (-2.54%)

08/05/20 Barclays
Activision Blizzard price target raised to $98 from $90 at Barclays
08/05/20 Morgan Stanley
Activision Blizzard price target raised to $100 from $88 at Morgan Stanley
08/05/20 UBS
Activision Blizzard price target raised to $106 from $84 at UBS
08/05/20 Oppenheimer
Activision Blizzard price target raised to $95 from $75 at Oppenheimer
TTWO Take-Two
$176.18 /

-1.07 (-0.60%)

08/04/20
Fly Intel: Top five analyst downgrades
08/04/20 MKM Partners
Take-Two price target raised to $190 from $165 at MKM Partners
08/04/20 Wedbush
Take-Two price target raised to $210 from $170 at Wedbush
08/04/20 Oppenheimer
Take-Two price target raised to $190 from $155 at Oppenheimer
GME GameStop
$4.59 /

+0.16 (+3.61%)

06/11/20 Ascendiant
GameStop price target raised to $4 from $3 at Ascendiant
06/10/20 Baird
GameStop significant challenges remain ahead, says Baird
04/21/20 Baird
GameStop FY20 EPS target cut at Baird
03/27/20 Baird
GameStop trneds to remain weak despite recent increase, says Baird
NTDOY Nintendo
$0.00 /

+ (+0.00%)

07/29/20 Goldman Sachs
Nintendo resumed with a Buy at Goldman Sachs
07/16/20 Citi
Nintendo price target raised to 59,000 yen from 47,000 yen at Citi
06/24/20
Fly Intel: Top five analyst downgrades
06/24/20 Wedbush
Nintendo downgraded to Neutral at Wedbush as catalysts may prove 'elusive'
EA Electronic Arts
$145.54 /

-0.77 (-0.53%)

07/31/20
Fly Intel: Top five analyst upgrades
07/31/20 JPMorgan
Electronic Arts price target raised to $150 from $127 at JPMorgan
07/31/20 MKM Partners
Electronic Arts price target raised to $160 from $144 at MKM Partners
07/31/20 KeyBanc
Electronic Arts upgraded to Overweight from Sector Weight at KeyBanc
UBSFY Ubisoft
$0.00 /

+ (+0.00%)

07/23/20 JPMorgan
Ubisoft price target raised to EUR 82 from EUR 79 at JPMorgan
07/17/20 Oddo BHF
Ubisoft downgraded to Neutral from Buy at Oddo BHF
07/13/20 Jefferies
Ubisoft downgraded to Hold from Buy at Jefferies
07/13/20 Societe Generale
Ubisoft downgraded to Hold from Buy at Societe Generale
MSFT Microsoft
$212.86 /

-0.46 (-0.22%)

08/05/20 Morgan Stanley
Morgan Stanley says TikTok US operations could be 'compelling' fit for Microsoft
08/04/20 Wedbush
Wedbush sees 75%-80% chance of Microsoft buying TikTok's U.S. operations
08/04/20 Oppenheimer
TikTok presents 'unique opportunity' for Microsoft, says Oppenheimer
08/03/20 Wedbush
Wedbush sees a TikTok deal as big bet from Microsoft on social media space
FB Facebook
$250.14 /

+0.7 (+0.28%)

08/05/20 HSBC
HSBC bumps up Facebook target to $195, maintains Reduce rating
08/04/20 Argus
Facebook price target raised to $300 from $270 at Argus
08/03/20 DA Davidson
Pinterest price target raised to $28 from $19 at DA Davidson
AMZN Amazon.com
$3,202.57 /

+66.59 (+2.12%)

08/03/20 Morgan Stanley
ADT Inc. price target raised to $17 from $7 at Morgan Stanley
07/31/20 BMO Capital
Amazon.com price target raised to $3,700 from $3,500 at BMO Capital
07/31/20 RBC Capital
Amazon.com price target raised to $3,800 from $3,300 at RBC Capital
07/31/20 Guggenheim
Amazon.com price target raised to $3,600 from $2,700 at Guggenheim
UBSFY Ubisoft
$0.00 /

+ (+0.00%)

TTWO Take-Two
$176.18 /

-1.07 (-0.60%)

NTDOY Nintendo
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.86 /

-0.46 (-0.22%)

GME GameStop
$4.59 /

+0.16 (+3.61%)

FB Facebook
$250.14 /

+0.7 (+0.28%)

EA Electronic Arts
$145.54 /

-0.77 (-0.53%)

ATVI Activision Blizzard
$84.15 /

-2.19 (-2.54%)

AMZN Amazon.com
$3,202.57 /

+66.59 (+2.12%)

UBSFY Ubisoft
$0.00 /

+ (+0.00%)

TTWO Take-Two
$176.18 /

-1.07 (-0.60%)

NTDOY Nintendo
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.86 /

-0.46 (-0.22%)

GME GameStop
$4.59 /

+0.16 (+3.61%)

FB Facebook
$250.14 /

+0.7 (+0.28%)

EA Electronic Arts
$145.54 /

-0.77 (-0.53%)

ATVI Activision Blizzard
$84.15 /

-2.19 (-2.54%)

AMZN Amazon.com
$3,202.57 /

+66.59 (+2.12%)

TTWO Take-Two
$176.18 /

-1.07 (-0.60%)

NTDOY Nintendo
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.86 /

-0.46 (-0.22%)

GME GameStop
$4.59 /

+0.16 (+3.61%)

FB Facebook
$250.14 /

+0.7 (+0.28%)

EA Electronic Arts
$145.54 /

-0.77 (-0.53%)

ATVI Activision Blizzard
$84.15 /

-2.19 (-2.54%)

AMZN Amazon.com
$3,202.57 /

+66.59 (+2.12%)

TTWO Take-Two
$176.18 /

-1.07 (-0.60%)

MSFT Microsoft
$212.86 /

-0.46 (-0.22%)

GME GameStop
$4.59 /

+0.16 (+3.61%)

FB Facebook
$250.14 /

+0.7 (+0.28%)

EA Electronic Arts
$145.54 /

-0.77 (-0.53%)

ATVI Activision Blizzard
$84.15 /

-2.19 (-2.54%)

AMZN Amazon.com
$3,202.57 /

+66.59 (+2.12%)

MSFT Microsoft
$212.86 /

-0.46 (-0.22%)

AMZN Amazon.com
$3,202.57 /

+66.59 (+2.12%)

Hot Stocks
Zscaler Internet Access achieves FedRAMP 'In Process' status » 08:18
08/05/20
08/05
08:18
08/05/20
08:18
ZS

Zscaler

$132.43 /

-0.18 (-0.14%)

Zscaler announced Zscaler…

Zscaler announced Zscaler Internet Access has achieved Federal Risk and Authorization Management Program "In Process" status at the High Impact level. ZIA, the first secure internet gateway solution to earn FedRAMP certification, is being sponsored for High Impact by a U.S. Department of Defense Command.

ShowHide Related Items >><<
ZS Zscaler
$132.43 /

-0.18 (-0.14%)

ZS Zscaler
$132.43 /

-0.18 (-0.14%)

07/16/20 Wedbush
Zscaler price target raised to $150 from $100 at Wedbush
07/09/20 Citi
Citi upgrades Zscaler to Buy on durability of flexible workforce trend
07/09/20 Citi
Zscaler upgraded to Buy from Neutral at Citi
07/07/20 Rosenblatt
Zscaler price target raised to $135 from $115 at Rosenblatt
ZS Zscaler
$132.43 /

-0.18 (-0.14%)

ZS Zscaler
$132.43 /

-0.18 (-0.14%)

ZS Zscaler
$132.43 /

-0.18 (-0.14%)

ZS Zscaler
$132.43 /

-0.18 (-0.14%)

Tuesday
On The Fly
Game On: EA, Take-Two report net bookings hike amid pandemic » 12:27
08/04/20
08/04
12:27
08/04/20
12:27
SNE

Sony

$83.01 /

+1.72 (+2.12%)

, SGAMY

Sega Sammy Holdings

$0.00 /

+ (+0.00%)

, EA

Electronic Arts

$145.01 /

+2.73 (+1.92%)

, TTWO

Take-Two

$174.65 /

+6.64 (+3.95%)

, NTDOY

Nintendo

$0.00 /

+ (+0.00%)

, ATVI

Activision Blizzard

$85.18 /

+0.415 (+0.49%)

, UBSFY

Ubisoft

$0.00 /

+ (+0.00%)

, MSFT

Microsoft

$211.25 /

-5.35 (-2.47%)

, GOOG

Alphabet

$1,461.06 /

-11.9 (-0.81%)

, GOOGL

Alphabet Class A

$1,468.42 /

-14.36 (-0.97%)

, TCEHY

Tencent

$0.00 /

+ (+0.00%)

, GME

GameStop

$4.58 /

+0.43 (+10.36%)

"Game On" is The Fly's…

Open Full Text

ShowHide Related Items >><<
UBSFY Ubisoft
$0.00 /

+ (+0.00%)

TTWO Take-Two
$174.65 /

+6.64 (+3.95%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

SNE Sony
$83.01 /

+1.72 (+2.12%)

NTDOY Nintendo
$0.00 /

+ (+0.00%)

MSFT Microsoft
$211.25 /

-5.35 (-2.47%)

GOOG Alphabet
$1,461.06 /

-11.9 (-0.81%)

GME GameStop
$4.58 /

+0.43 (+10.36%)

EA Electronic Arts
$145.01 /

+2.73 (+1.92%)

ATVI Activision Blizzard
$85.18 /

+0.415 (+0.49%)

SNE Sony
$83.01 /

+1.72 (+2.12%)

08/05/20 Oppenheimer
Sony price target raised to $100 from $70 at Oppenheimer
07/30/20
Fly Intel: Top five analyst initiations
07/29/20 Goldman Sachs
Sony resumed with a Conviction Buy at Goldman Sachs
07/16/20 Guggenheim
Best Buy price target raised to $100 from $90 at Guggenheim
SGAMY Sega Sammy Holdings
$0.00 /

+ (+0.00%)

06/09/20 JPMorgan
Sega Sammy Holdings downgraded to Neutral from Overweight at JPMorgan
EA Electronic Arts
$145.01 /

+2.73 (+1.92%)

07/31/20
Fly Intel: Top five analyst upgrades
07/31/20 JPMorgan
Electronic Arts price target raised to $150 from $127 at JPMorgan
07/31/20 MKM Partners
Electronic Arts price target raised to $160 from $144 at MKM Partners
07/31/20 KeyBanc
Electronic Arts upgraded to Overweight from Sector Weight at KeyBanc
TTWO Take-Two
$174.65 /

+6.64 (+3.95%)

08/04/20
Fly Intel: Top five analyst downgrades
08/04/20 MKM Partners
Take-Two price target raised to $190 from $165 at MKM Partners
08/04/20 Wedbush
Take-Two price target raised to $210 from $170 at Wedbush
08/04/20 Oppenheimer
Take-Two price target raised to $190 from $155 at Oppenheimer
NTDOY Nintendo
$0.00 /

+ (+0.00%)

07/29/20 Goldman Sachs
Nintendo resumed with a Buy at Goldman Sachs
07/16/20 Citi
Nintendo price target raised to 59,000 yen from 47,000 yen at Citi
06/24/20
Fly Intel: Top five analyst downgrades
06/24/20 Wedbush
Nintendo downgraded to Neutral at Wedbush as catalysts may prove 'elusive'
ATVI Activision Blizzard
$85.18 /

+0.415 (+0.49%)

08/05/20 Barclays
Activision Blizzard price target raised to $98 from $90 at Barclays
08/05/20 Morgan Stanley
Activision Blizzard price target raised to $100 from $88 at Morgan Stanley
08/05/20 UBS
Activision Blizzard price target raised to $106 from $84 at UBS
08/05/20 Oppenheimer
Activision Blizzard price target raised to $95 from $75 at Oppenheimer
UBSFY Ubisoft
$0.00 /

+ (+0.00%)

07/23/20 JPMorgan
Ubisoft price target raised to EUR 82 from EUR 79 at JPMorgan
07/17/20 Oddo BHF
Ubisoft downgraded to Neutral from Buy at Oddo BHF
07/13/20 Jefferies
Ubisoft downgraded to Hold from Buy at Jefferies
07/13/20 Societe Generale
Ubisoft downgraded to Hold from Buy at Societe Generale
MSFT Microsoft
$211.25 /

-5.35 (-2.47%)

08/07/20 DA Davidson
Datadog price target raised to $80 from $52 at DA Davidson
08/05/20 Morgan Stanley
Morgan Stanley says TikTok US operations could be 'compelling' fit for Microsoft
08/04/20 Wedbush
Wedbush sees 75%-80% chance of Microsoft buying TikTok's U.S. operations
08/04/20 Oppenheimer
TikTok presents 'unique opportunity' for Microsoft, says Oppenheimer
GOOG Alphabet
$1,461.06 /

-11.9 (-0.81%)

08/03/20 Goldman Sachs
ADT Inc. price target raised to $17 from $9 at Goldman Sachs
08/03/20 William Blair
Alarm.com downgraded to Market Perform from Outperform at William Blair
08/03/20 Morgan Stanley
ADT Inc. price target raised to $17 from $7 at Morgan Stanley
08/03/20 Credit Suisse
ADT Inc. price target raised to $8.70 from $7 at Credit Suisse
GOOGL Alphabet Class A
$1,468.42 /

-14.36 (-0.97%)

08/03/20 William Blair
Alarm.com downgraded at William Blair on ADT/Google overhang
TCEHY Tencent
$0.00 /

+ (+0.00%)

08/03/20 Morgan Stanley
Sohu.com named a Research Tactical Idea at Morgan Stanley
07/27/20 Barclays
Tencent price target raised to $75 from $63 at Barclays
07/14/20 Citi
Tencent price target raised to HK$649 from HK$541 at Citi
07/08/20 Mizuho
Tencent price target raised to HK$475 from HK$410 at Mizuho
GME GameStop
$4.58 /

+0.43 (+10.36%)

06/11/20 Ascendiant
GameStop price target raised to $4 from $3 at Ascendiant
06/10/20 Baird
GameStop significant challenges remain ahead, says Baird
04/21/20 Baird
GameStop FY20 EPS target cut at Baird
03/27/20 Baird
GameStop trneds to remain weak despite recent increase, says Baird
UBSFY Ubisoft
$0.00 /

+ (+0.00%)

TTWO Take-Two
$174.65 /

+6.64 (+3.95%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

SNE Sony
$83.01 /

+1.72 (+2.12%)

NTDOY Nintendo
$0.00 /

+ (+0.00%)

MSFT Microsoft
$211.25 /

-5.35 (-2.47%)

GOOG Alphabet
$1,461.06 /

-11.9 (-0.81%)

GME GameStop
$4.58 /

+0.43 (+10.36%)

EA Electronic Arts
$145.01 /

+2.73 (+1.92%)

ATVI Activision Blizzard
$85.18 /

+0.415 (+0.49%)

UBSFY Ubisoft
$0.00 /

+ (+0.00%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

SNE Sony
$83.01 /

+1.72 (+2.12%)

NTDOY Nintendo
$0.00 /

+ (+0.00%)

MSFT Microsoft
$211.25 /

-5.35 (-2.47%)

GOOG Alphabet
$1,461.06 /

-11.9 (-0.81%)

GME GameStop
$4.58 /

+0.43 (+10.36%)

EA Electronic Arts
$145.01 /

+2.73 (+1.92%)

ATVI Activision Blizzard
$85.18 /

+0.415 (+0.49%)

TTWO Take-Two
$174.65 /

+6.64 (+3.95%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

SNE Sony
$83.01 /

+1.72 (+2.12%)

MSFT Microsoft
$211.25 /

-5.35 (-2.47%)

GME GameStop
$4.58 /

+0.43 (+10.36%)

EA Electronic Arts
$145.01 /

+2.73 (+1.92%)

TTWO Take-Two
$174.65 /

+6.64 (+3.95%)

SNE Sony
$83.01 /

+1.72 (+2.12%)

MSFT Microsoft
$211.25 /

-5.35 (-2.47%)

GME GameStop
$4.58 /

+0.43 (+10.36%)

EA Electronic Arts
$145.01 /

+2.73 (+1.92%)

ATVI Activision Blizzard
$85.18 /

+0.415 (+0.49%)

MSFT Microsoft
$211.25 /

-5.35 (-2.47%)

Conference/Events
William Blair to hold a virtual conference » 09:55
08/04/20
08/04
09:55
08/04/20
09:55
RCUS

Arcus Biosciences

$20.42 /

-0.61 (-2.90%)

, AGEN

Agenus

$3.20 /

-0.055 (-1.69%)

, EXEL

Exelixis

$23.06 /

-0.64 (-2.70%)

, CALA

Calithera Biosciences

$4.85 /

-0.02 (-0.41%)

, RGEN

Repligen

$155.50 /

-3.02 (-1.91%)

, PIRS

Pieris Pharmaceuticals

$2.68 /

-0.025 (-0.92%)

, CYAD

Celyad

$9.87 /

+ (+0.00%)

, FATE

Fate Therapeutics

$32.33 /

-0.92 (-2.77%)

, CLLS

Cellectis

$17.44 /

+ (+0.00%)

, AUTL

Autolus Therapeutics

$13.92 /

+ (+0.00%)

, GRTS

Gritstone Oncology

$3.35 /

+0.03 (+0.90%)

, ADPT

Adaptive Biotechnologies

$39.49 /

+0.12 (+0.30%)

, TBIO

Translate Bio

$15.60 /

-0.14 (-0.89%)

, EBS

Emergent BioSolutions

$122.01 /

+4.045 (+3.43%)

, ITCI

Intra-Cellular

$20.77 /

-0.15 (-0.72%)

, KRTX

Karuna Therapeutics

$86.82 /

-0.68 (-0.78%)

, ASMB

Assembly Biosciences

$23.15 /

+0.03 (+0.13%)

, NCNA

NuCana

$6.55 /

+0.4 (+6.50%)

, AXSM

Axsome Therapeutics

$74.50 /

-1.82 (-2.38%)

, OVID

Ovid Therapeutics

$6.61 /

-0.16 (-2.36%)

, ALLK

Allakos

$78.92 /

-0.57 (-0.72%)

, NBIX

Neurocrine

$124.09 /

+0.92 (+0.75%)

, XENE

Xenon Pharmaceuticals

$11.51 /

+ (+0.00%)

, CRSP

Crispr Therapeutics

$91.70 /

-0.85 (-0.92%)

, BEAM

Beam Therapeutics

$19.00 /

+0.03 (+0.16%)

, GBT

Global Blood Therapeutics

$68.59 /

-2.08 (-2.94%)

, IONS

Ionis Pharmaceuticals

$58.45 /

-0.78 (-1.32%)

, RTRX

Retrophin

$20.19 /

+ (+0.00%)

Biotech Focus Virtual…

Biotech Focus Virtual Conference 2020 will be held on August 4-6 beginning at 10 am on August 4. Webcast Link

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RTRX Retrophin
$20.19 /

+ (+0.00%)

RGEN Repligen
$155.50 /

-3.02 (-1.91%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CYAD Celyad
$9.87 /

+ (+0.00%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

AGEN Agenus
$3.20 /

-0.055 (-1.69%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
AGEN Agenus
$3.20 /

-0.055 (-1.69%)

01/09/20 B. Riley FBR
Arbutus Biopharma price target raised to $6 from $3 at B. Riley FBR
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 B. Riley FBR
Agenus resumed with a Buy at B. Riley FBR
11/19/19 B. Riley FBR
Agenus resumed with a Buy at B. Riley FBR
EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 Truist
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

05/11/20 Citi
Calithera Biosciences price target raised to $10 from $7 at Citi
05/08/20 H.C. Wainwright
Calithera Biosciences price target raised to $9.50 from $7 at H.C. Wainwright
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Jefferies
Jefferies starts Calithera at Buy ahead of three data catalysts
RGEN Repligen
$155.50 /

-3.02 (-1.91%)

06/30/20 H.C. Wainwright
Repligen price target raised to $151 from $143 at H.C. Wainwright
05/27/20 Stifel
Repligen price target raised to $150 from $135 at Stifel
05/07/20 Craig-Hallum
Repligen price target raised to $145 from $120 at Craig-Hallum
05/07/20 H.C. Wainwright
Repligen price target raised to $143 from $100 at H.C. Wainwright
PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

03/13/20 Baird
Baird upgrades Pieris Pharmaceuticals as pipeline updates expected
03/13/20 Baird
Pieris Pharmaceuticals upgraded to Outperform from Neutral at Baird
03/12/20 H.C. Wainwright
Increased visibility in 2020 expected for Pieris, says H.C. Wainwright
01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
CYAD Celyad
$9.87 /

+ (+0.00%)

03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

06/10/20 Oppenheimer
Fate Therapeutics price target raised to $40 from $34 at Oppenheimer
06/09/20 Piper Sandler
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
CLLS Cellectis
$17.44 /

+ (+0.00%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

07/14/20 BTIG
Gritstone Oncology price target lowered to $17 from $31 at BTIG
ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

07/07/20 H.C. Wainwright
Translate Bio price target raised to $32 from $18 at H.C. Wainwright
07/06/20
Fly Intel: Top five analyst initiations
07/06/20 William Blair
Translate Bio initiated with an Outperform at William Blair
06/26/20 Truist
Translate Bio initiated with a Buy at SunTrust
EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

07/17/20 Cantor Fitzgerald
Emergent BioSolutions price target raised to $110 from $85 at Cantor Fitzgerald
07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

06/04/20 Cantor Fitzgerald
Cantor reiterates $37 target on Intra-Cellular ahead of Phase 3 data
03/03/20 BTIG
Intra-Cellular price target lowered to $68 from $73 at BTIG
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
10/17/19 Baird
Assembly Biosciences abstract data encouraging, says Baird
NCNA NuCana
$6.55 /

+0.4 (+6.50%)

07/24/20
Fly Intel: Top five analyst initiations
07/24/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
07/23/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
01/27/20 William Blair
NuCana undervalued as first patients dosed in Phase 3 study, says William Blair
AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 Truist
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
06/18/20 Cantor Fitzgerald
Ovid Therapeutics price target raised to $13 from $7 at Cantor Fitzgerald
05/22/20 Cantor Fitzgerald
Zynerba price target raised to $21 from $12 at Cantor Fitzgerald
05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
ALLK Allakos
$78.92 /

-0.57 (-0.72%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

08/04/20 Canaccord
Neurocrine price target raised to $145 from $134 at Canaccord
08/04/20 SVB Leerink
Neurocrine price target raised to $120 from $105 at SVB Leerink
08/04/20 Piper Sandler
Neurocrine price target raised to $145 from $141 at Piper Sandler
08/04/20 H.C. Wainwright
Neurocrine price target raised to $140 from $131 at H.C. Wainwright
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
07/20/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
06/01/20
Fly Intel: Top five analyst initiations
CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

07/28/20 Needham
Crispr Therapeutics price target raised to $105 from $84 at Needham
07/28/20 Wells Fargo
Crispr Therapeutics price target raised to $110 from $95 at Wells Fargo
07/28/20 Oppenheimer
Crispr Therapeutics price target raised to $105 from $89 at Oppenheimer
07/28/20 Barclays
Crispr Therapeutics price target raised to $102 from $65 at Barclays
BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
03/02/20 JPMorgan
Beam Therapeutics initiated with an Overweight at JPMorgan
03/02/20 Wedbush
Beam Therapeutics initiated with an Outperform at Wedbush
GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
07/13/20 BofA
Global Blood Therapeutics initiated with a Buy at BofA
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/12/20 Wells Fargo
Global Blood's Oxbryta efficacy bar 'tough to surpass,' says Wells Fargo
IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

07/20/20 BMO Capital
Alnylam price target raised to $196 from $173 at BMO Capital
06/05/20 Citi
Ionis Pharmaceuticals price target raised to $80 from $71 at Citi
05/12/20 RBC Capital
Ionis Pharmaceuticals initiated with an Outperform at RBC Capital
04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
RTRX Retrophin
$20.19 /

+ (+0.00%)

07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RTRX Retrophin
$20.19 /

+ (+0.00%)

RGEN Repligen
$155.50 /

-3.02 (-1.91%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

AGEN Agenus
$3.20 /

-0.055 (-1.69%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

  • 16
    Jul
  • 01
    Jul
  • 26
    Jun
  • 09
    Jun
  • 09
    Jun
  • 29
    May
  • 13
    May
  • 16
    Apr
  • 06
    Feb
  • 23
    Jan
  • 23
    Jan
  • 22
    Jan
  • 24
    Jan
  • 08
    Jan
  • 19
    Dec
  • 12
    Dec
  • 21
    Nov
  • 21
    Nov
  • 04
    Oct
  • 18
    Sep
  • 12
    Sep
  • 12
    Sep
  • 07
    Aug
RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

Conference/Events
William Blair to hold a virtual conference » 08:49
08/04/20
08/04
08:49
08/04/20
08:49
RCUS

Arcus Biosciences

$21.03 /

+1.34 (+6.81%)

, AGEN

Agenus

$3.25 /

+0.205 (+6.73%)

, EXEL

Exelixis

$23.70 /

+0.64 (+2.78%)

, CALA

Calithera Biosciences

$4.87 /

+0.15 (+3.18%)

, RGEN

Repligen

$158.52 /

+7.46 (+4.94%)

, PIRS

Pieris Pharmaceuticals

$2.71 /

+0.135 (+5.25%)

, CYAD

Celyad

$9.87 /

+ (+0.00%)

, FATE

Fate Therapeutics

$33.25 /

+2 (+6.40%)

, CLLS

Cellectis

$17.44 /

+1.77 (+11.30%)

, AUTL

Autolus Therapeutics

$13.92 /

+0.72 (+5.45%)

, GRTS

Gritstone Oncology

$3.32 /

+0.115 (+3.59%)

, ADPT

Adaptive Biotechnologies

$39.37 /

+1.99 (+5.32%)

, TBIO

Translate Bio

$15.74 /

+0.56 (+3.69%)

, EBS

Emergent BioSolutions

$117.97 /

+6.755 (+6.07%)

, ITCI

Intra-Cellular

$20.92 /

+1.11 (+5.60%)

, KRTX

Karuna Therapeutics

$87.50 /

+5.89 (+7.22%)

, ASMB

Assembly Biosciences

$23.12 /

+0.9 (+4.05%)

, NCNA

NuCana

$6.15 /

+0.65 (+11.82%)

, AXSM

Axsome Therapeutics

$76.32 /

+4.97 (+6.97%)

, OVID

Ovid Therapeutics

$6.77 /

+0.32 (+4.96%)

, ALLK

Allakos

$79.49 /

+4.36 (+5.80%)

, NBIX

Neurocrine

$123.17 /

+2.8 (+2.33%)

, XENE

Xenon Pharmaceuticals

$11.51 /

+0.55 (+5.02%)

, CRSP

Crispr Therapeutics

$92.55 /

+7.15 (+8.37%)

, BEAM

Beam Therapeutics

$18.97 /

-0.31 (-1.61%)

, GBT

Global Blood Therapeutics

$70.67 /

+3.24 (+4.80%)

, IONS

Ionis Pharmaceuticals

$59.23 /

+1.7 (+2.95%)

, RTRX

Retrophin

$20.19 /

+0.385 (+1.94%)

Biotech Focus Virtual…

Biotech Focus Virtual Conference 2020 will be held on August 4-6 beginning at 10 am on August 4. Webcast Link

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

RGEN Repligen
$158.52 /

+7.46 (+4.94%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CYAD Celyad
$9.87 /

+ (+0.00%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

AGEN Agenus
$3.25 /

+0.205 (+6.73%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
AGEN Agenus
$3.25 /

+0.205 (+6.73%)

01/09/20 B. Riley FBR
Arbutus Biopharma price target raised to $6 from $3 at B. Riley FBR
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 B. Riley FBR
Agenus resumed with a Buy at B. Riley FBR
11/19/19 B. Riley FBR
Agenus resumed with a Buy at B. Riley FBR
EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 Truist
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

05/11/20 Citi
Calithera Biosciences price target raised to $10 from $7 at Citi
05/08/20 H.C. Wainwright
Calithera Biosciences price target raised to $9.50 from $7 at H.C. Wainwright
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Jefferies
Jefferies starts Calithera at Buy ahead of three data catalysts
RGEN Repligen
$158.52 /

+7.46 (+4.94%)

06/30/20 H.C. Wainwright
Repligen price target raised to $151 from $143 at H.C. Wainwright
05/27/20 Stifel
Repligen price target raised to $150 from $135 at Stifel
05/07/20 Craig-Hallum
Repligen price target raised to $145 from $120 at Craig-Hallum
05/07/20 H.C. Wainwright
Repligen price target raised to $143 from $100 at H.C. Wainwright
PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

03/13/20 Baird
Baird upgrades Pieris Pharmaceuticals as pipeline updates expected
03/13/20 Baird
Pieris Pharmaceuticals upgraded to Outperform from Neutral at Baird
03/12/20 H.C. Wainwright
Increased visibility in 2020 expected for Pieris, says H.C. Wainwright
01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
CYAD Celyad
$9.87 /

+ (+0.00%)

03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

06/10/20 Oppenheimer
Fate Therapeutics price target raised to $40 from $34 at Oppenheimer
06/09/20 Piper Sandler
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

07/14/20 BTIG
Gritstone Oncology price target lowered to $17 from $31 at BTIG
ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

07/07/20 H.C. Wainwright
Translate Bio price target raised to $32 from $18 at H.C. Wainwright
07/06/20
Fly Intel: Top five analyst initiations
07/06/20 William Blair
Translate Bio initiated with an Outperform at William Blair
06/26/20 Truist
Translate Bio initiated with a Buy at SunTrust
EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

07/17/20 Cantor Fitzgerald
Emergent BioSolutions price target raised to $110 from $85 at Cantor Fitzgerald
07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

06/04/20 Cantor Fitzgerald
Cantor reiterates $37 target on Intra-Cellular ahead of Phase 3 data
03/03/20 BTIG
Intra-Cellular price target lowered to $68 from $73 at BTIG
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
10/17/19 Baird
Assembly Biosciences abstract data encouraging, says Baird
NCNA NuCana
$6.15 /

+0.65 (+11.82%)

07/24/20
Fly Intel: Top five analyst initiations
07/24/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
07/23/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
01/27/20 William Blair
NuCana undervalued as first patients dosed in Phase 3 study, says William Blair
AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 Truist
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
06/18/20 Cantor Fitzgerald
Ovid Therapeutics price target raised to $13 from $7 at Cantor Fitzgerald
05/22/20 Cantor Fitzgerald
Zynerba price target raised to $21 from $12 at Cantor Fitzgerald
05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
ALLK Allakos
$79.49 /

+4.36 (+5.80%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

08/04/20 Canaccord
Neurocrine price target raised to $145 from $134 at Canaccord
08/04/20 SVB Leerink
Neurocrine price target raised to $120 from $105 at SVB Leerink
08/04/20 Piper Sandler
Neurocrine price target raised to $145 from $141 at Piper Sandler
08/04/20 H.C. Wainwright
Neurocrine price target raised to $140 from $131 at H.C. Wainwright
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
07/20/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
06/01/20
Fly Intel: Top five analyst initiations
CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

07/28/20 Needham
Crispr Therapeutics price target raised to $105 from $84 at Needham
07/28/20 Wells Fargo
Crispr Therapeutics price target raised to $110 from $95 at Wells Fargo
07/28/20 Oppenheimer
Crispr Therapeutics price target raised to $105 from $89 at Oppenheimer
07/28/20 Barclays
Crispr Therapeutics price target raised to $102 from $65 at Barclays
BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
03/02/20 JPMorgan
Beam Therapeutics initiated with an Overweight at JPMorgan
03/02/20 Wedbush
Beam Therapeutics initiated with an Outperform at Wedbush
GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
07/13/20 BofA
Global Blood Therapeutics initiated with a Buy at BofA
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/12/20 Wells Fargo
Global Blood's Oxbryta efficacy bar 'tough to surpass,' says Wells Fargo
IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

07/20/20 BMO Capital
Alnylam price target raised to $196 from $173 at BMO Capital
06/05/20 Citi
Ionis Pharmaceuticals price target raised to $80 from $71 at Citi
05/12/20 RBC Capital
Ionis Pharmaceuticals initiated with an Outperform at RBC Capital
04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

RGEN Repligen
$158.52 /

+7.46 (+4.94%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

AGEN Agenus
$3.25 /

+0.205 (+6.73%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

  • 16
    Jul
  • 01
    Jul
  • 26
    Jun
  • 09
    Jun
  • 09
    Jun
  • 29
    May
  • 13
    May
  • 16
    Apr
  • 06
    Feb
  • 23
    Jan
  • 23
    Jan
  • 22
    Jan
  • 24
    Jan
  • 08
    Jan
  • 19
    Dec
  • 12
    Dec
  • 21
    Nov
  • 21
    Nov
  • 04
    Oct
  • 18
    Sep
  • 12
    Sep
  • 12
    Sep
  • 07
    Aug
RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

Over a week ago
Hot Stocks
Lexicon enters into agreement with TerSera for sale of XERMELO » 08:02
07/30/20
07/30
08:02
07/30/20
08:02
LXRX

Lexicon

$1.72 /

-0.025 (-1.43%)

Lexicon Pharmaceuticals…

Lexicon Pharmaceuticals and TerSera Therapeutics LLC announced that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicon's rights, title and interest in XERMELO. Pursuant to the terms of the agreement, TerSera will pay Lexicon approximately $159 million in cash at closing, which includes a $155 million upfront payment and approximately $4 million for existing inventory. Lexicon may receive additional development, regulatory and sales milestone payments of up to an aggregate of $65 million for the development and commercialization of telotristat ethyl in patients with biliary tract cancer. Additionally, Lexicon will be eligible to receive mid-teens royalties on net sales of XERMELO in biliary tract cancer. As part of the transaction, TerSera has agreed to assume the currently ongoing TELE-ABC Phase 2 clinical study of XERMELO in biliary tract cancer patients and offer employment to at least 20 Lexicon employees currently dedicated to XERMELO. The transaction is expected to close in the third quarter of 2020, subject to customary closing conditions.

ShowHide Related Items >><<
LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

07/21/20 Stifel
Stifel says incremental value of Lexicon data 'likely negligible at best'
12/20/19 Stifel
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
12/11/19 Gabelli
Lexicon downgraded to Hold from Buy at Gabelli
LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

Hot Stocks
Lexicon aligns business around R&D assets, with focus on Phase 2 LX9211 program » 08:01
07/30/20
07/30
08:01
07/30/20
08:01
LXRX

Lexicon

$1.72 /

-0.025 (-1.43%)

Lexicon Pharmaceuticals…

Lexicon Pharmaceuticals announced that it is realigning its business around its research and development assets, with a focus on its LX9211 neuropathic pain program, now in Phase 2 clinical development. In that regard: Initiation of Phase 2 Clinical Development of LX9211. Lexicon has initiated patient screening in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of diabetic peripheral neuropathic pain that is expected to enroll approximately 300 patients at 30 U.S. sites. Lexicon is preparing for additional Phase 2 studies of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1, in other areas of neuropathic pain based on promising results in multiple preclinical models of neuropathic pain and a favorable Phase 1 clinical safety profile. Sale of XERMELO to TerSera. Lexicon entered into an asset purchase and sale agreement with TerSera Therapeutics LLC for the sale of Lexicon's XERMELO product and related assets for up to $224 million in upfront and milestone payments, consisting of approximately $159 million in cash at closing and up to $65 million in development, regulatory and sales milestones relating to biliary tract cancer, plus eligibility for mid-teens royalties on net sales of XERMELO in biliary tract cancer. As part of the transaction, TerSera has agreed to assume the currently ongoing TELE-ABC Phase 2 clinical study of XERMELO in biliary tract cancer patients and offer employment to at least 20 Lexicon employees currently dedicated to XERMELO. MTS Health Partners, L.P. served as financial advisor and WilmerHale served as legal counsel to Lexicon. Debt Reduction. Lexicon will use the upfront proceeds from the XERMELO sale to substantially reduce its debt, including full repayment of its $150 million secured term loan.

ShowHide Related Items >><<
LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

07/21/20 Stifel
Stifel says incremental value of Lexicon data 'likely negligible at best'
12/20/19 Stifel
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
12/11/19 Gabelli
Lexicon downgraded to Hold from Buy at Gabelli
LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.